Enanta Pharmaceuticals initiates Phase Ia study of oral antibiotic
The Phase Ia, double-blind, placebo controlled study for EDP-322 announced is a single ascending dose trial in healthy volunteers. The clinical development program for EDP-322 will include the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.